

**CHANGE - ANNOUNCEMENT OF CESSATION::CESSATION OF AN EXECUTIVE DIRECTOR**

## Issuer &amp; Securities

## Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

## Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

## Stapled Security

No

## Announcement Details

## Announcement Title

Change - Announcement of Cessation

## Date &amp; Time of Broadcast

10-Apr-2023 07:49:16

## Status

New

## Announcement Sub Title

Cessation of an Executive Director

## Announcement Reference

SG230410OTHRTRVP

## Submitted By (Co./ Ind. Name)

Lim See Wah

## Designation

Executive Chairman and CEO

## Description (Please provide a detailed description of the event in the box below)

Cessation of Mr Tan Chwee Choon as an Executive Director of the Company.

This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: +65 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

## Additional Details

## Name Of Person

Tan Chwee Choon

Age

66

Is effective date of cessation known?

Yes

If yes, please provide the date

26/04/2023

Detailed Reason (s) for cessation

Mr Tan Chwee Choon ("Mr Tan") will be retiring as Director of the Company pursuant to Regulation 97 of the Constitution of the Company. Mr Tan indicated that he would not seek for re-election as Director of the Company and would retire at the conclusion of the Annual General Meeting of the Company to be held on 26 April 2023.

Further, the Sponsor, after having interviewed Mr Tan, is satisfied that, other than as disclosed in this announcement, there are no material reasons for the retirement of Mr Tan as an Executive Director of the Company.

The Company expresses its gratitude to Mr Tan for his valuable contributions during his tenure of service.

Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?

No

Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?

No

Any other relevant information to be provided to shareholders of the listed issuer?

No

Date of Appointment to current position

12/12/2017

Does the AC have a minimum of 3 members (taking into account this cessation)?

Yes

Number of Independent Directors currently resident in Singapore (taking into account this cessation)

4

Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months

1

Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)

Executive Director

Role and responsibilities

Responsible for managing the Indochina operations.

Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries

Nil

[Shareholding interest in the listed issuer and its subsidiaries?](#)

Yes

---

[Shareholding Details](#)

Mr Tan Chwee Choon has a direct interest of 38,045,560 ordinary shares (12.32%) in the Company.

---

[Past \(for the last 5 years\)](#)

DAC Pharmalab Pte Ltd, Singapore  
Ocean Healthcare (M) Sdn. Bhd., Malaysia

---

[Present](#)

Within the Group:

Hyphens Pharma Pte. Ltd., Singapore  
Ocean Health Pte. Ltd., Singapore  
Pan-Malayan Pharmaceuticals Pte Ltd, Singapore  
Hyphens Pharma Philippines, Inc., Philippines

Subsequent to this announcement, Mr Tan will also step down as a director of the above-mentioned Group's subsidiaries on 26 April 2023.

Outside the Group:

LTT Investments Pte. Ltd., Singapore

---